CD19 and BCMA – “What if This Is As Good as It Gets?”

Authored by Cello Health BioConsulting, now part of Lumanity

I’m no fortune-teller.  But I can predict with a reasonable amount of certainty that, in the next week or so, we’ll see a press release that more or less says the following: “Mega venture round for CAR-T therapy platform company coming out of stealth-mode with an A-list cadre of scientific co-founders, a C-suite that knows how to raise funds and get the job done, and a value proposition pointed at the target painted on the backs of early-mover products.”  While money is clearly not falling from the sky, there are massive opportunities for cell therapy newcos with their ducks in a row.